iORGANBIO lands Mitsui Chemicals investment
The Morrisville biotech and the Japanese materials maker will combine an AI-run cell lab with InnoCell culture plates to make more consistent human cells and organoids.

iORGANBIO, a Morrisville biotechnology company, announced on Nov. 10 that it has received an investment from Mitsui Chemicals through 321Catalyst, the Japanese chemical maker's corporate venture capital fund. The amount was not disclosed.
Founded in July 2024 and led by CEO Daniel Delubac, iORGANBIO designs and manufactures human cells and organoids for drug discovery and regenerative medicine. Its platform links AI, single-cell analysis and robotics in a closed-loop autonomous lab built to produce target cells with a high degree of uniformity and reproducibility.
Mitsui Chemicals will contribute its materials design work, including its InnoCell cell culture plates. The companies aim to improve cell and organoid quality and to make cell types that have been hard to manufacture, and they plan to explore drug discovery tools, including efficacy and safety testing, that could complement or serve as alternatives to animal testing.
"We are thrilled to announce our growing relationship with Mitsui Chemicals," said Delubac. "We are excited to partner with iORGANBIO in contributing to greater efficiency in drug discovery and advancements in cell therapy and regenerative medicine," said Shunsuke Fujii, PhD, GM of New Business Incubation Center, Mitsui Chemicals.
About this story
By Sotwire Desk. Written by Sotwire Desk from the sources below. Not a company attestation.
Sotwire Desk. Written by a named Sotwire editor from the sources cited below. Not a company attestation. Sotwire corrects errors publicly.
Key facts
- iORGANBIO
- Morrisville, NC
- Funding
- Desk reported
- Sotwire Desk
- Mitsui Chemicals, via 321Catalyst CVC fund
- Not disclosed
- July 2024
- Daniel Delubac, PhD
Key events
- iORGANBIO founded
- Mitsui Chemicals investment announced
Sources
- iORGANBIO and Mitsui Chemicals Collaborate to Advance AI-Driven Human Cell and Organoid Manufacturing · GlobeNewswire / iORGANBIO · accessed 2026-11-16
- Mitsui Chemicals Invests in iOrganBio, Developer of a Human Cell Design and Manufacturing Platform · Mitsui Chemicals · accessed 2026-11-16

